Reece's Piece's In a Diabetes World

Dulaglutide, Trulicity, has received a new FDA indication for prevention of primary (person has no established heart disease, or history of heart attack or stroke) AND secondary (person has established heart disease, or history of heart attack or stroke) reduction of major adverse cardiovascular (heart) events (i.e. heart attack or stroke) in adults with type 2 diabetes. Adults with type 2 diabetes have an elevated risk for heart attacks and strokes so proactive prevention is vital. What makes this new indication particularly important is that it is for prevention in person with or without established heart disease.

https://www.healio.com/endocrinology/diabetes/news/online/%7Ba3e6dcf7-baa1-48e3-bbfa-cde2d3ba9a20%7D/fda-grants-dulaglutide-cv-indication-for-diabetes-with-or-without-established-cvd?utm_source=selligent&utm_medium=email&utm_campaign=endocrinology%20news&m_bt=4557970002905

Please share your thoughts and subscribe to receive my blogs.

#Dulaglutide #primary #secondary #prevention #heart

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Unfortunately, we have two recalls this week. FDA has issues a class I recall (most serious) for certain Medtronic MiniMed 600 series (please click on link below for specifics) due to incorrect insulin dosing which has caused 2,175 injuries and one death.

https://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-minimed-insulin-pumps-incorrect-insulin-dosing

Secondly, Eisai manufacturer of weight loss medication, lorcaserin (Belviq), has agreed to voluntarily withdrawal lorcaserin from the market due to concerns of cancer risk.

https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market

Please share your thoughts and subscribe to receive my blogs.

#FDA #recall #Medtronic #Belviq

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

As a person with prediabetes who takes metformin, I am excited to share that the FDA recommends no recall on metformin. This is a follow up from Tuesday’s Daily Piece regarding the testing of metformin for NDMA. Please share this good news.

https://www.medscape.com/viewarticle/924866

Please share your thoughts and subscribe to receive my blogs.

#metformin #no #recall #FDA

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

If you recall in 2019, several generic medications were pulled from the market due to having unacceptable levels of N-Nitrosodimethylamine (NDMA) impurity as NDMA increases risk of cancer. Concerns regarding the level of NDMA in generic metformin surfaced in late 2019. Good news came out earlier this week that the FDA found no tested samples of generic metformin contained unacceptable levels of NDMA important. Please click below to found additional details regarding the tested samples of metformin.

https://www.raps.org/news-and-articles/news-articles/2020/2/ndma-in-metformin-fda-finds-low-levels-in-only-2

Please share your thoughts and subscribe to receive my blogs.

#metformin #NDMA #FDA

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

CVS Health announced a new program, RxZERO, which sounds amazing. It promises to eliminate out of pocket expenses for diabetes medications. Wow!!! Oh exciting until you read closely that it requires employees with diabetes to use only approved generic diabetes medications – no branded medications. So this “amazing” program does not eliminate copays for SGLT-2 inhibitors, GLP-1 agonists, most DPP-IV inhibitors, branded insulin.

https://www.benefitnews.com/news/cvs-health-eliminates-out-of-pocket-costs-for-diabetes-medications

Please share your thoughts and subscribe to receive my blogs.

#RxZERO #disappointed #generic #drugs

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

I don’t know about you but I like the idea of 3 meds in 1 pill. Well we now have a new 3 in 1 diabetes combination medication on the market. Trijardy XR contains empagliflozin (Jardiance) (SGLT2 inhibitor with additional indication to reduce risk of cardiovascular (heart related) death in adults with type 2 diabetes and established cardiovascular disease), linagliptin (Tradjenta) (DPP-IV inhibitor) and metformin XR (backbone of treatment for type 2 diabetes).

https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-only-triple-combination-tablet-jardiancer-adults

Please share your thoughts and subscribe to receive my blogs.

#3-in-1 #combination #TrijardyXR

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

I am thrilled to share the exciting new name of diabetes care and education specialists for the specialty formerly known as diabetes educators. This new title for the specialty more accurately captures the role of the specialty. Certified diabetes educators are now certified diabetes care and education specialists. As a diabetes care and education specialists myself, I do more than simply educate. American Association of Diabetes Educators (AADE) is now the Association of Diabetes Care and Education Specialist (ADCES). Having served on the Board of Directors of AADE during the process of changing name of specialty and association, I confidentiality say that the research backs the name change as well as input from key stakeholders. For more information on the timely and essential name change, please click below.

https://www.diabeteseducator.org/practice/new-name-title

Please share your thoughts and subscribe to receive my blogs.

#ACDES #new #name #specialty

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

In a recent study published in Annals of Internal Medicine, sodium glucose cotransporter-2 (SGLT2) inhibitors were found to have a reduced risk for gout as compared to glucagon like peptide 1 (GLP-1) agonist. In this study patient taking SGLT2 inhibitor had 36% reduced risk of developing gout. The study design, population-based cohort study, is not the most robust study design as well as gout risk factors were not accessed in the study. While this is promising, more studies are needed.

https://annals.org/aim/article-abstract/2758844/assessing-risk-gout-sodium-glucose-cotransporter-2-inhibitors-patients-type

Please share your thoughts and subscribe to receive my blogs.

#gout #reduction #SGLT-2 inhibitors

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

The benefits or harms of diabetes medications on cardiovascular health matters in a major way. In recent years, medications particularly select GLP-1 agonists and SGLT-2 inhibitors have shown major cardiovascular benefits. Ozempic, a GLP-1 agonist, now has a FDA indication for reduction of major adverse cardiovascular events (i.e. heart attack, stroke) in adults with type 2 diabetes and known (diagnosed) heart disease. Please click more for details.

https://www.prnewswire.com/news-releases/fda-approves-ozempic-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-and-known-heart-disease-updates-rybelsus-label-300988672.html

Please share your thoughts and subscribe to receive my blogs.

#heart #reduction #Ozempic #indication

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

We all know that cost of insulin is HIGH!!! Several of the insulin manufacturers are implementing various cost lowering and/or savings programs that aim to address the pricing concerns. Eli Lilly in 2019 created lower-priced version of meal time insulin, Humalog. Now in 2020, they will now be introducing two additional lower-priced versions of their insulins, Humalog Junior KwikPen and Humalog Mix 75/25. The list price will be $265.20 for a pack of five KwikPens. While this is certainly a move in the right direction, I am still deeply concerned about the cost of insulin.

https://www.reuters.com/article/us-lilly-insulin/eli-lilly-to-launch-half-priced-versions-of-two-more-insulin-products-idUSKBN1ZD1JN

Please share your thoughts and subscribe to receive my blogs.

#lower #priced #insulin #diabetes

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.